Key result
Long-term estrogen therapy in men with myocardial infarction was feasible, with only 15 of 109 patients leaving the clinic for reasons other than death over an aggregate of 900 months.
Why the study?
Is long-term estrogen therapy feasible and tolerated in men with myocardial infarction?
Observational (n=109)
Is long-term estrogen therapy feasible and tolerated in men with myocardial infarction?
This early report demonstrated the feasibility of conducting long-term clinical studies of estrogen therapy in men with myocardial infarction.
Answers are grounded in this paper and cite their sources.
Supports feasibility of long-term estrogen studies post-MI; leaves open efficacy and safety in randomized trials.
Long-term therapy with estrogens, in well-tolerated doses, was studied in men with myocardial infarction. This report indicates the feasibility of such studies. Of 109 men treated with estrogen for an aggregate of over 900 months, only 15 left the clinic for reasons other than death. Of these 15, 8 left before the appearance of any clinical manifestation of the estrogen therapy. The dosage schedule called for small initial doses and gradual increases until minor evidences were observed. Breast tenderness was the first finding in all but one patient. Long-term clinical studies of estrogen therapy in men, therefore, appear entirely feasible.
No takes yet. Share an insight, caveat, or question.
Jessie Marmorston (1960) conducted an observational in Myocardial Infarction (n=109). Estrogen therapy was evaluated on Feasibility (leaving the clinic for reasons other than death). Long-term estrogen therapy in men with myocardial infarction was feasible, with only 15 of 109 patients leaving the clinic for reasons other than death over an aggregate of 900 months.
Synapse has enriched 10 related papers. Consider them for comparative context: